Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

BACKGROUND: In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)—mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR). METHODS: A multicenter phase two study was performed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Antill, Yoland, Kok, Peey-Sei, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Smith, Deborah, Spurdle, Amanda, Barnes, Elizabeth, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Andrews, John, Stockler, Martin R, Mileshkin, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190057/
https://www.ncbi.nlm.nih.gov/pubmed/34103352
http://dx.doi.org/10.1136/jitc-2020-002255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190057/
https://www.ncbi.nlm.nih.gov/pubmed/34103352
http://dx.doi.org/10.1136/jitc-2020-002255

Ejemplares similares